An empirical analysis of overall survival in drug approvals by the US FDA (2006-2023).

About 32% of all oncology drug approvals have evidence for an improvement in OS. Higher standards are needed in drug regulation to ensure that approved drugs are delivering better patient outcomes, specifically in regards to survival.